Tags

Type your tag names separated by a space and hit enter

[Mutations conferring resistance to first-line anti-tuberculosis drugs in Peru: a systematic review of the literature].
Rev Peru Med Exp Salud Publica 2019 Oct-Dec; 36(4):636-645RP

Abstract

OBJECTIVE.

To systematize available information regarding mutations that confer resistance to first-line anti-tuberculosis drugs.

MATERIALS AND METHODS.

A systematic review of the scientific literature was conducted to identify articles that reported mutations conferring resistance to first-line anti-tuberculosis drugs. This search emphasized resistance to isoniazid and rifampicin drugs in M. tuberculosis strains of Peruvian patients. The search was performed on PubMed and LILACS (Latin American and Caribbean Health Sciences Literature).

RESULTS.

Fourteen (14) articles were included, of which three reported mutations associated with resistance to isoniazid, six to rifampicin, eight to pyrazinamide and one to ethambutol. All mutations to isoniazid or rifampicin were identified directly or indirectly by the molecular diagnostic test GenoType MTBDRplus® v2.0. The greatest variability of mutations was determined in resistance to pyrazinamide.

CONCLUSIONS.

There is a great variability of mutations associated with resistance to anti-tuberculosis drugs that have been reported in Peru, and they are systematized in this report. These mutations must be taken into account for the development of diagnostic devices or selection of diagnostic tests to be applied in our country.

Authors+Show Affiliations

Instituto Nacional de Salud, Lima, Perú.Instituto Nacional de Salud, Lima, Perú.Instituto Nacional de Salud, Lima, Perú.Instituto Nacional de Salud, Lima, Perú.

Pub Type(s)

English Abstract
Journal Article

Language

spa

PubMed ID

31967255

Citation

Vigo, Aiko, et al. "[Mutations Conferring Resistance to First-line Anti-tuberculosis Drugs in Peru: a Systematic Review of the Literature]." Revista Peruana De Medicina Experimental Y Salud Publica, vol. 36, no. 4, 2019, pp. 636-645.
Vigo A, Solari L, Santos D, et al. [Mutations conferring resistance to first-line anti-tuberculosis drugs in Peru: a systematic review of the literature]. Rev Peru Med Exp Salud Publica. 2019;36(4):636-645.
Vigo, A., Solari, L., Santos, D., & Puyén, Z. M. (2019). [Mutations conferring resistance to first-line anti-tuberculosis drugs in Peru: a systematic review of the literature]. Revista Peruana De Medicina Experimental Y Salud Publica, 36(4), pp. 636-645. doi:10.17843/rpmesp.2019.364.4722.
Vigo A, et al. [Mutations Conferring Resistance to First-line Anti-tuberculosis Drugs in Peru: a Systematic Review of the Literature]. Rev Peru Med Exp Salud Publica. 2019;36(4):636-645. PubMed PMID: 31967255.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Mutations conferring resistance to first-line anti-tuberculosis drugs in Peru: a systematic review of the literature]. AU - Vigo,Aiko, AU - Solari,Lely, AU - Santos,David, AU - Puyén,Zully M, Y1 - 2020/01/17/ PY - 2019/08/06/received PY - 2019/11/06/accepted PY - 2020/1/23/entrez SP - 636 EP - 645 JF - Revista peruana de medicina experimental y salud publica JO - Rev Peru Med Exp Salud Publica VL - 36 IS - 4 N2 - OBJECTIVE.: To systematize available information regarding mutations that confer resistance to first-line anti-tuberculosis drugs. MATERIALS AND METHODS.: A systematic review of the scientific literature was conducted to identify articles that reported mutations conferring resistance to first-line anti-tuberculosis drugs. This search emphasized resistance to isoniazid and rifampicin drugs in M. tuberculosis strains of Peruvian patients. The search was performed on PubMed and LILACS (Latin American and Caribbean Health Sciences Literature). RESULTS.: Fourteen (14) articles were included, of which three reported mutations associated with resistance to isoniazid, six to rifampicin, eight to pyrazinamide and one to ethambutol. All mutations to isoniazid or rifampicin were identified directly or indirectly by the molecular diagnostic test GenoType MTBDRplus® v2.0. The greatest variability of mutations was determined in resistance to pyrazinamide. CONCLUSIONS.: There is a great variability of mutations associated with resistance to anti-tuberculosis drugs that have been reported in Peru, and they are systematized in this report. These mutations must be taken into account for the development of diagnostic devices or selection of diagnostic tests to be applied in our country. SN - 1726-4642 UR - https://www.unboundmedicine.com/medline/citation/31967255/[Mutations_conferring_resistance_to_first-line_anti-tuberculosis_drugs_in_Peru:_a_systematic_review_of_the_literature] DB - PRIME DP - Unbound Medicine ER -
Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
Unbound MEDLINE
Unbound PubMed app for Windows